#LCSM Chat Topic 6/15: Patient Reported Outcomes (PROs)—more effective than some approved cancer drugs for advanced disease

With the proliferation of smartphones and personal tracking devices (such as Fitbits), technology has the means for cancer patients to provide feedback to their healthcare providers about their symptoms and side effects of treatment.  Such feedback is called “patient reported outcomes,” or PROs.  However, PROs are difficult to measure in a consistent manner, and thus far have not been incorporated into many cancer center clinics or clinical trials. But times are changing.  One of the big news items to come out of the huge American Society of Clinical Oncology (ASCO) Annual Meeting… Read More

#LCSM Chat Topic 5/18: What’s PFS Got to Do with It?

For our chat on 5/18/17, starting at 8 PM Eastern, 5 PM Pacific, we’ll cover several key trial results and the potential implications of them.  While each has the potential to be practice changing, all three have the primary endpoint of progression-free survival (PFS) but, to our knowledge, don’t necessarily improve overall survival (OS).  It is interesting that the differences between the settings and trial designs have led many lung cancer experts to favor adoption of some of these results but not necessarily others. But what do patients and caregivers think of… Read More

#LCSM Chat Topic 4/6: Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?

  Our topic for the next #LCSM Chat on Thursday, April 6th at 5 PM Pacific/ 8 PM Eastern is “Who Needs Research Anyway: How Have You Been Impacted by Lung Cancer Research?” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD) In its most recent budget outline, the Trump administration is looking to propose an 18% cut to the National Institute of Health’s (NIH; @NIH) $31.7 billion budget (#trumpbudget).  In addition to this funding cut, the Trump administration proposes to 1) reorganize the current NIH institute structure and 2)… Read More